NCT06209619 - CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 29, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

B-Cell Non-Hodgkin Lymphoma-RecurrentDiffuse Large B-Cell Lymphoma-RecurrentFollicular Lymphoma-RecurrentHigh Grade B-Cell Lymphoma-RecurrentPrimary Mediastinal Large B-Cell Lymphoma-RecurrentTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-RecurrentB-Cell Non-Hodgkin Lymphoma-RefractoryDiffuse Large B-Cell Lymphoma-RefractoryFollicular Lymphoma-RefractoryHigh Grade B-Cell Lymphoma-RefractoryPrimary Mediastinal Large B-Cell Lymphoma-RefractoryTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Refractory

Interventions

PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo PET/CT

DRUG

Golcadomide

Given PO

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

BIOLOGICAL

Rituximab

Given IV

Trial Locations (1)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus